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SUPPLEMENT: Genetic invalidation of Lp-PLA2 as a therapeutic target 1 
 2 
Systematic review of East Asian studies 3 
We searched the Medline electronic library on 04/07/2014 by combining the following terms related to 4 
the PLA2G7 genetic variant (see eFigure 1), without language restriction:  5 
(Lp-PLA2 OR LpPLA2 OR Lp-PLA(2) OR 1-alkyl-2-acetylglycerophosphocholine esterase OR PAFAH OR 6 
PAF-AH OR PLA2G7 OR platelet activating factor acetylhydrolase OR lipoprotein associated 7 
phospholipase A2)  8 
AND  9 
(gene OR genes  OR polymorph* OR allel* OR phenotyp* OR SNP OR chromosom* OR variant* OR 10 
mutat* OR locus OR loci OR Genes [Mesh] OR Polymorphism, genetic [Mesh] OR RFLP OR V279F OR 11 
PLA2G7 or rs16875954) 12 
Titles, abstracts and full text versions of identified articles were reviewed independently by at least two 13 
of three investigators (JG, AT, DFF). Studies were included if they reported on, or allowed calculation 14 
of, the association of the loss of function variant V279F with coronary heart disease (provided 15 
myocardial infarction was part of the outcome definition), or the risk factors in healthy individuals. 16 
Additionally, we searched the NIHR GWAS catalogue (https://www.genome.gov/26525384; accessed 17 
04/07/2014) to identify additional GWAS studies of coronary disease in East Asians. eFigure 1 18 
describes the selection process, which identified 16 independent studies overall that contributed data. 19 
 20 
Systematic review of randomized controlled darapladib trials 21 
We searched the Medline electronic library on 23/02/2015 for the term “darapladib” without language 22 
restriction. Titles, abstracts and full text versions of identified articles were reviewed independently by 23 
two investigators (JG, DFF). The search strategy identified 75 publications in total. Five of these 24 
publications reported on the results of five randomized placebo controlled clinical trials of darapladib. 25 
Three of those trials reported on Lp-PLA2 activity and cardiovascular risk factors, two trials reported on 26 
coronary heart disease endpoints.  27 
Proxy variants 28 
In cases where information on the genetic variants was not available, we identified suitable proxy 29 
variants for the relevant population using 1000 Genomes, Phase I release data. For the modest impact 30 
variant rs1051931, which is common in Europeans, we identified suitable proxy variants in Europeans: 31 
rs7756935 (r2=1.00, D’=1.00) and rs3799277 (r2=0.96, D'=1.00). For the loss of function variant 32 
rs76863441 (previously rs16874954), common in East Asians, we identified rs1805018 as a suitable 33 
proxy variant in Japanese populations (r2=0.94, D’=1.0).  34 
Adjustment for principal components in genetic analyses 35 
Principal component analysis (PCA) was performed (separately for Europeans and South Asians) in the 36 
component studies of the CHD Exome+ Consortium to identify ethnic outliers. Following standard 37 
sample and variant QC, further stringent variant QC (call rate>99% and Hardy-Weinberg p-38 
value<1x10-4) was performed on common variants (minor allele frequency>0.05), followed by 39 
stepwise pruning until no residual linkage disequilbrium (r2>0.2) was observed. We further excluded 40 
variants in known coronary disease loci, leaving 19,256 variants within the Europeans and 17,968 41 
variants within the South Asians for the PCA. PCA was then performed on a standardised genotype 42 
matrix created using the Singular Value Decomposition (SVD) function implemented in the R package 43 
'irlba'. 219 Europeans and 10 South Asians who were ancestral outliers, defined as being at least 3 44 
 
standard deviations away from the cluster mean, were excluded. The PCA was rerun after excluding 45 
these samples to obtain principal components that could be used to account for population 46 
substructure. The first principal component was included in the statistical model for each ancestral 47 
group. 48 
 49 
 50 
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Supplementary figures and tables 118 
eFigure1: Search strategy and study flow diagram for systematic review and meta-analysis of V279F 119 
(rs76863441) and cardiovascular disease 120 
 121 
 
eFigure 2: Meta-analysis of associations of genetic variants in PLA2G7 or darapladib with Lp-PLA2 activity. 122 
 123 
* proxy variant rs7756935 (r2=1.00); MORGAM = MONICA, Risk, Genetics, Archiving, and Monograph; PROMIS = Pakistan Risk of Myocardial Infarction Study; PROSPER = Pravastatin in 124 
elderly individuals at risk of vascular disease trial 125 
+Estimate of difference in Lp-PLA2 activity per rare V279F allele using a random-effects meta-analysis with inverse-variance weighting is -46.3% (95% CI: -50.5% to -42.0%) 126 
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eFigure 3: Meta-analysis of associations of genetic variants in PLA2G7 or darapladib with coronary heart disease risk. 127 
 128 
BRAVE = Bangladesh Risk of Acute Vascular Events Study; C4D = the Coronary Artery Disease Genetics consortium; CARDIoGRAM = the transatlantic Coronary Artery Disease Genome-wide 129 
Replication and Meta-analysis consortium; CCHS = Copenhagen City Heart Study; CHS= Cardiovascular Health Study; CGPS = Copenhagen General Population Study; CIHDS = Copenhagen 130 
Ischaemic Heart Disease Study; EPIC = European Prospective Investigation into Cancer and Nutrition Study; MORGAM = MONICA, Risk, Genetics, Archiving, and Monograph; PROMIS = 131 
Pakistan Risk of Myocardial Infarction Study; PROSPER = Pravastatin in elderly individuals at risk of vascular disease trial; WOSCOPS = West of Scotland Coronary Prevention Study; * proxy 132 
variant rs3799277 (r2=0.96 with rs1051931 in Europeans); ** proxy variant rs1805018 (r2=0.94 with rs76863441 in Japanese). CHD estimate from darapladib clinical trials uses the 133 
endpoint fatal CHD, MI or urgent revascularisation (primary endpoint for SOLID-TIMI-52, and pre-specified secondary endpoint for STABILITY).   134 
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eFigure 4: Individual and combined estimates for loss of function variants in Europeans and South Asians 135 
136 
*Estimate based on one carrier of Val279Phe, hence the confidence interval has been omitted. There were no individuals with Lp-PLA2 activity levels and the splice donor loss of function 137 
variant c.109+2T>C (rs142974898) measured. With an allele frequency of 0.01% (~8 times less common than the other loss of function variants), this variant was too rare for individual 138 
variant testing. The variant contributed, however, to the aggregated test over all four loss of function variants presented in the main manuscript 139 
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 eTable 1: Loss of function variants in PLA2G7 and annotation 140 
Protein change or 
context* 
Rsid (if available) Observed in 1KG or 
ESP† 
Primary source Reference for in vivo or in vitro evidence Selected for present 
study 
69 D>G rs201315851 Neither Re-sequencing study Song Pharmacogenomics 2011 No 
82 R>H  rs144983904 1KG, ESP Re-sequencing study Song Pharmacogenomics 2011 Yes 
134 W>STOP rs200454121 Neither Re-sequencing study Song Pharmacogenomics 2011 No 
181 D>G NA Neither Re-sequencing study Song Pharmacogenomics 2011 No 
273 S>A NA Neither UniProt Tjoelker LW, JBC 1995 No 
273 S>F NA Neither Re-sequencing study Song Pharmacogenomics 2011 No 
279 V>F rs76863441 / rs16874954 1KG Uniprot Several Yes 
281 Q>R rs201256712 Neither Uniprot Yamada Y, Biochem Biophys Res Commun 1997 No 
283 L>P rs200303358 Neither Re-sequencing study Song Pharmacogenomics 2011 No 
286 D>A NA  Neither UniProt Tjoelker LW, JBC 1995 No 
286 D>N NA  Neither Uniprot Tjoelker LW, JBC 1995 No 
287 Q>STOP rs140020965 1KG, ESP ExAC consortium   Yes 
296 D>A NA Neither Uniprot Tjoelker LW, JBC 1995 No 
296 D>N NA Neither Uniprot Tjoelker LW, JBC 1995 No 
351 H>A NA Neither Uniprot Tjoelker LW, JBC 1995 No 
Splice donor 
variant 
rs142974898 1KG ExAC consortium   Yes 
* refers to the canonical transcript ENST00000274793 †(1KG = observed in 1000 Genomes project; ESP = observed in Exome sequencing project). Only loss of function variants reported in 141 
either 1KG or ESP were included in this study (entries shaded in light blue). 142 
 eTable 2: Summary of Caucasian & South Asian studies/consortia  143 
Endpoint / 
phenotype 
Type of data Study / 
consortium 
Endpoint definition N 
cases 
N 
controls 
Reference 
(PMID) 
Coronary 
disease 
De-novo 
genotyping 
BRAVE Confirmed MI meeting all of the following criteria: 
i) presented within 24 hours of the onset of 
sustained clinical symptoms suggestive of MI 
lasting longer than 20 minutes, including chest 
pain and breathlessness; ii) had ECG changes 
indicative of MI (new pathologic Q waves, at least 
1 mm ST elevation in any 2 or more contiguous 
limb leads or a new left bundle branch block, or 
new persistent ST-T wave changes diagnostic of a 
non-Q wave MI) with a subsequent confirmation 
by troponin-I measurements; and iii) had no 
previous cardiovascular diseases; defined as self-
reported history of angina, MI, coronary 
revascularisation, transient ischaemic attack, 
stroke or evidence of CHD on prior ECG or in other 
medical records. 
2971 2784 25930055 
 De-novo 
genotyping 
CCHS MI or major coronary event defined according to 
IHD (World Health Organization International 
Classification of Diseases-Eighth Revision, codes 
410 to 414; International Classification of Diseases-
Tenth Revision, codes I20 to I25) ascertained by 
reviewing all hospital admissions and diagnoses 
entered in the national Danish Patient Registry and 
all causes of death entered in the national Danish 
Causes of Death Registry. 
2020 6087 19509380 
 De-novo 
genotyping 
CIHDS/CGPS WHO-ICD 8 codes 410 to 414 or ICD 10 codes I20 
to I25. Diagnosis of acute coronary syndrome and 
stenosis or atherosclerosis on coronary 
angiography and/or positive results on exercise 
electrocardiography. 
8079 10,367 23265341; 
17635890 
 De-novo 
genotyping 
EPIC Incident CHD cases defined as fatal and non-fatal 
MI and other major acute coronary events, 
according to ICD-10 codes I20-I25. All centres have 
recorded cause-specific mortality through 
mortality registries and/or active follow-up, and 
have ascertained and validated incident fatal and 
non-fatal CHD through a combination of methods 
(eg, morbidity registers, general practice records, 
MONICA registries, self-report, clinical records). 
9810 10,970 17295097 
 De-novo 
genotyping 
MORGAM Incident definite or possible MI or coronary death, 
or unstable angina during follow‐up, coronary 
revascularization during follow‐up, documented 
MI at baseline, or an unclassifiable coronary death 
during follow‐up 
2153 2118 15561751 
 De-novo 
genotyping 
PROMIS Confirmed MI meeting all of the following criteria: 
i) presented within 24 hours of the onset of 
sustained clinical symptoms suggestive of MI 
lasting longer than 20 minutes, including chest 
pain and breathlessness; ii) had ECG changes 
indicative of MI (new pathologic Q waves, at least 
1 mm ST elevation in any 2 or more contiguous 
limb leads or a new left bundle branch block, or 
new persistent ST-T wave changes diagnostic of a 
non-Q wave MI) with a subsequent confirmation 
by troponin-I measurements; and iii) had no 
previous cardiovascular diseases; defined as self-
reported history of angina, MI, coronary 
revascularisation, transient ischaemic attack, 
stroke or evidence of CHD on prior ECG or in other 
medical records. 
10,137 11,935 19404752 
 De-novo 
genotyping 
PROSPER Death from coronary heart disease or nonfatal MI. 641 638 12457784 
 De-novo 
genotyping 
WOSCOPS Death from coronary heart disease or nonfatal MI. 659 687 7566020 
 Summary C4D MI and other major coronary events (~90% of 11,146 10,940 21378988 
 data, 
published 
cases); angiographic stenosis only (~10% of cases) 
 Summary 
data, 
published 
CARDIoGRAM MI and other major coronary events (~90% of 
cases); angiographic stenosis only (~10% of cases) 
20,315 58,415 21378990 
Lp-PLA2 
activity 
Summary 
data, 
published 
CHARGE 
consortium, 
composed of: 
Cardiovascular 
Health Study, 
Framingham 
Heart Study and 
Rotterdam Study 
Validated colourimetric or radioactive assays 
(diaDexus CAM Kit, diaDexus, Inc., San Francisco, 
CA, USA or Perkin Elmer Life Sciences, Inc., 
Waltham, MA, USA) 
 12,113 22003152 
 
Tabular data, 
published 
ARIC Automated Colorimetric Activity Method assay 
(diaDexus Inc., South San Francisco, CA) using a 
Beckman Coulter (Olympus) AU400e autoanalyzer 
 8564 25587968 
 
De-novo 
genotyping 
MORGAM 
(FINRISK 
component) 
Colorimetric Activity Method assay, Diadexus, Inc., 
San Francisco, CA 
 944 15561751 
 
De-novo 
genotyping 
PROSPER Colorimetric Activity Method assay, Diadexus, Inc., 
San Francisco, CA 
 1229 20005516 
LDL-C 
Summary 
data, 
published 
GLGC Validated commercially available assays  89,888 24097068 
 
De-novo 
genotyping 
BRAVE Validated enzymatic assay (Roche Diagnostics)  5737 25930055 
 
De-novo 
genotyping 
CCHS Validated colorimetric assay  8056 19509380 
 
De-novo 
genotyping 
CIHDS/CGPS Validated colorimetric assay  18021 23265341; 
17635890 
 
De-novo 
genotyping 
EPIC Validated assay (Roche Diagnostics)  17886 17295097 
 
De-novo 
genotyping 
PROMIS Validated enzymatic assay (Roche Diagnostics)  20885 19404752 
 
De-novo 
genotyping 
PROSPER Calculated using Friedewald formula  1268 12457784 
 
De-novo 
genotyping 
WOSCOPS Calculated using Friedewald formula  1337 7566020 
HDL-C 
Summary 
data, 
published 
GLGC Validated commercially available assays  94,311 24097068 
 
De-novo 
genotyping 
BRAVE Validated enzymatic assay (Roche Diagnostics)  5739 25930055 
 
De-novo 
genotyping 
CCHS Validated colorimetric assay  8096 19509380 
 
De-novo 
genotyping 
CIHDS/CGPS Validated colorimetric assay  18072 23265341; 
17635890 
 
De-novo 
genotyping 
EPIC Validated assay (Roche Diagnostics)  18238 17295097 
 
De-novo 
genotyping 
MORGAM Validated enzymatic assay after isolation of HDL  4269 15561751 
 
De-novo 
genotyping 
PROMIS Validated enzymatic assay (Roche Diagnostics)  20919 19404752 
 
De-novo 
genotyping 
PROSPER Validated assay at the Centre for Disease Control 
certified central lipoprotein laboratory in Glasgow. 
 1268 12457784 
 
De-novo 
genotyping 
WOSCOPS Validated assay at the Centre for Disease Control 
certified central lipoprotein laboratory in Glasgow. 
 1337 7566020 
Triglycerides 
Summary 
data, 
published 
GLGC Validated commercially available assays  91,013 24097068 
 
De-novo 
genotyping 
BRAVE Validated enzymatic assay (Roche Diagnostics)  5738  
 
De-novo 
genotyping 
CCHS Validated colorimetric assay  8068 19509380 
 
De-novo 
genotyping 
CIHDS/CGPS Validated colorimetric assay  18120 23265341; 
17635890 
 
De-novo 
genotyping 
EPIC Validated assay (Roche Diagnostics)   18238 17295097 
  
De-novo 
genotyping 
MORGAM Validated assays  2316 15561751 
 
De-novo 
genotyping 
PROMIS Validated enzymatic assay (Roche Diagnostics)  20935 19404752 
 
De-novo 
genotyping 
PROSPER Validated assay at the Centre for Disease Control 
certified central lipoprotein laboratory in Glasgow. 
 1268 12457784 
 
De-novo 
genotyping 
WOSCOPS Validated assay at the Centre for Disease Control 
certified central lipoprotein laboratory in Glasgow. 
 1337 7566020 
BMI 
Summary 
data, 
published 
GIANT Predominantly measured (few individual studies 
with self-report) 
 126,142 23754948 
 
De-novo 
genotyping 
BRAVE Measured  5266 25930055 
 
De-novo 
genotyping 
CCHS Measured  8082 19509380 
 
De-novo 
genotyping 
CIHDS/CGPS Measured  14254 23265341; 
17635890 
 
De-novo 
genotyping 
EPIC Measured or self-report  21117 17295097 
 
De-novo 
genotyping 
MORGAM Measured  4264 15561751 
 
De-novo 
genotyping 
PROMIS Measured  20994 19404752 
 
De-novo 
genotyping 
PROSPER Measured  1268 12457784 
 
De-novo 
genotyping 
WOSCOPS Measured  1337 7566020 
Diastolic blood 
pressure 
Summary 
data, 
published 
ICBP Validated methods (eg, mercury 
sphygmomanometer, automated blood pressure 
monitoring systems) 
 69,239 21909115 
 
De-novo 
genotyping 
BRAVE Standard sphygmomanometer  5250 25930055 
 
De-novo 
genotyping 
CCHS Standard sphygmomanometer  8070 19509380 
 
De-novo 
genotyping 
CIHDS/CGPS Standard sphygmomanometer  13215 23265341; 
17635890 
 
De-novo 
genotyping 
EPIC Standard sphygmomanometer  15674 17295097 
 
De-novo 
genotyping 
MORGAM Simple mercury sphygmomanometer, random zero 
sphygmomanometer, or automated device 
 5755 15561751 
 
De-novo 
genotyping 
PROMIS Standard sphygmomanometer  20676 19404752 
 
De-novo 
genotyping 
PROSPER Standard mercury sphygmomanometer  1264 12457784 
 
De-novo 
genotyping 
WOSCOPS Standard mercury sphygmomanometer  1337 7566020 
Systolic blood 
pressure 
Summary 
data, 
published 
ICBP Validated methods (eg, mercury 
sphygmomanometer, automated blood pressure 
monitoring systems) 
 69,245 21909115 
 
De-novo 
genotyping 
BRAVE Standard sphygmomanometer  5250 25930055 
 
De-novo 
genotyping 
CCHS Standard sphygmomanometer  8070 19509380 
 
De-novo 
genotyping 
CIHDS/CGPS Standard sphygmomanometer  13218 23265341; 
17635890 
 
De-novo 
genotyping 
EPIC Standard sphygmomanometer  15676 17295097 
 
De-novo 
genotyping 
MORGAM Simple mercury sphygmomanometer, random zero 
sphygmomanometer, or automated device  
 5755 15561751 
 
De-novo 
genotyping 
PROMIS Standard sphygmomanometer  20686 19404752 
 
De-novo 
genotyping 
PROSPER Standard mercury sphygmomanometer  1264 12457784 
 
De-novo 
genotyping 
WOSCOPS Standard mercury sphygmomanometer  1337 7566020 
Insulin 
Summary 
data, 
published 
MAGIC Validated commercially available assays  38,238 20081858 
  
De-novo 
genotyping 
PROMIS Validated assay  8073 19404752 
 
De-novo 
genotyping 
PROSPER Validated assay, Mercodia; Diagenics, Milton 
Keynes, UK 
 1236 12457784 
Fasting 
glucose 
Summary 
data, 
published 
MAGIC Validated commercially available assays  46,186 20081858 
 
De-novo 
genotyping 
EPIC Validated assay (Roche Diagnostics)  2606 17295097 
 
De-novo 
genotyping 
PROMIS Validated assay (Roche Diagnostics)  4234 19404752 
 
De-novo 
genotyping 
PROSPER Validated assay  1222 12457784 
 
De-novo 
genotyping 
WOSCOPS Validated assay  1346 7566020 
eGFR 
Summary 
data, 
published 
CKDGen Serum creatinine calibrated to the US nationally 
representative National Health and Nutrition 
Examination Study (NHANES) standards. eGFR was 
estimated using the four-variable MDRD Study 
equation. 
 74,354 22479191 
 
De-novo 
genotyping 
EPIC Serum creatinine (Roche Diagnostics). eGFR was 
estimated using the four-variable MDRD Study 
equation. 
 17133 17295097 
 
De-novo 
genotyping 
PROMIS Creatinine via Jaffe method. eGFR was estimated 
using the four-variable MDRD Study equation. 
 12444 19404752 
 
De-novo 
genotyping 
PROSPER Creatinine via Jaffe method. eGFR was estimated 
using the four-variable MDRD Study equation. 
 1267 12457784 
 
De-novo 
genotyping 
WOSCOPS Creatinine via Jaffe method. eGFR was estimated 
using the four-variable MDRD Study equation. 
 1346 7566020 
C-reactive 
protein 
Summary 
data, 
published 
CHARGE Validated ELISA or similar methods  66,185 21300955 
 
De-novo 
genotyping 
CCHS Turbidimetry (Dako, Glostrup, Denmark)  7349 19509380 
 
De-novo 
genotyping 
CIHDS/CGPS Nephelometry (Dade Behring, Deerfield, Ill)  11,425 23265341; 
17635890 
 
De-novo 
genotyping 
EPIC Validated assay (Roche Diagnostics)  18231 17295097 
 
De-novo 
genotyping 
MORGAM Validated assays  971 15561751 
 
De-novo 
genotyping 
PROMIS Validated assay  1017 19404752 
 
De-novo 
genotyping 
PROSPER Turbidimetry (Roche UK, Welwyn Garden City, UK)  1239 12457784 
 
De-novo 
genotyping 
WOSCOPS Standardized in-house ELISA  1209 7566020 
 BRAVE = Bangladesh Risk of Acute Vascular Events Study; C4D = the Coronary Artery Disease Genetics consortium; 144 
CARDIoGRAM = the transatlantic Coronary Artery Disease Genome-wide Replication and Meta-analysis consortium; CCHS = 145 
Copenhagen City Heart Study; CHS= Cardiovascular Health Study; CGPS = Copenhagen General Population Study; CIHDS = 146 
Copenhagen Ischaemic Heart Disease Study; ELISA = Enzyme-linked immunosorbent assay; EPIC = European Prospective 147 
Investigation into Cancer and Nutrition Study; MORGAM = MONICA Risk, Genetics, Archiving and Monograph (subcohorts 148 
include: ATBC, Augsburg, Brianza, FINRISK, PRIME-Belfast, PRIME-Lille, PRIME-Strasbourg, PRIME-Toulouse); PROMIS = 149 
Pakistan Risk of Myocardial Infarction Study; PROSPER = Pravastatin in elderly individuals at risk of vascular disease trial; 150 
WOSCOPS = West of Scotland Coronary Prevention Study; Details for assessment methods used in the MORGAM cohort are 151 
available at: http://www.thl.fi/publications/morgam/qa/contents.htm 152 
 153 
 
eTable 3 : Characteristics of participants from the Exome+ consortium by case-status 154 
 155 
Numbers are mean (SD), NR=Not recorded  156 
 South Asian European 
 BRAVE PROMIS CCHS CGPS/CIHDS EPIC-CVD MORGAM PROSPER WOSCOPS 
 Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
N 2971 2874 10,137 11,935 2020 6087 8079 10,367 9810 10,970 2153 2118 641 638 659 687 
Male (n (%)) 2640 
(88.9) 
2467 
(88.6) 
8524 
(84.1) 
9054 
(75.9) 
1040 
(51.5) 
2553 
(41.9) 
5570 
(68.9) 
4706 
(45.4) 
6013 
(61.3) 
3779 
(34.5) 
1899 
(89.2) 
1753 
(82.8) 
403 
(62.9) 
305 
(47.8) 
659 
(100) 
687 
(100) 
Age (years) 52.1 
(10.5) 
50.2 
(10.1) 
53.7 
(10.2) 
56.2 
(9.1) 
65.7 
(10.9) 
55.3 
(15.4) 
63.8 
(10.9) 
55.4 
(12.7) 
58.8 
(8.6) 
51.4 
(9.6) 
59.2 
(7.7) 
58.4 
(8.4) 
75.6 
(3.5) 
76.4 
(3.6) 
56.3 
(5.4) 
55.0 
(5.8) 
Height (cm) 162.3 
(7.3) 
162.1 
(7.3) 
166.6 
(7.6) 
166.2 
(9.1) 
167.1 
(9.4) 
168.6 
(9.6) 
171.2 
(8.9) 
171.2 
(9.4) 
168.8 
(9.2) 
165.5 
(9.2) 
170.4 
(7.8) 
170.8 
(8.4) 
166.3 
(9.0) 
166.0 
(9.4) 
171.5 
(7.0) 
172.4 
(6.9) 
Weight (kg) 59.5 
(10.6) 
59.9 
(11.1) 
71.9 
(11.1) 
71.9 
(13.3) 
75.0 
(14.9) 
71.8 
(14.0) 
80.7 
(15.5) 
76.8 
(15.2) 
77.3 
(13.9) 
71.5 
(13.4) 
80.7 
(13.3) 
78.9 
(13.4) 
74.7 
(13.1) 
73.4 
(13.0) 
76.5 
(11.3) 
76.6 
(10.6) 
BMI (kg/m2) 22.5 
(3.5) 
22.8 
(3.8) 
25.9 
(4.0) 
26.1 
(4.8) 
26.8 
(4.5) 
25.2 
(4.2) 
27.2 
(4.4) 
26.1 
(4.3) 
27.1 
(4.1) 
26.1 
(4.4) 
27.8 
(4.1) 
27.0 
(3.9) 
27.0 
(4.0) 
26.6 
(4.1) 
26.0 
(3.3) 
25.7 
(3.0) 
WHR (-) 0.97 
(0.07) 
0.95 
(0.07) 
0.97 
(0.06) 
0.95 
(0.06) 
NR NR NR NR 0.90 
(0.09) 
0.84 
(0.09) 
0.95 
(0.08) 
0.91 
(0.09) 
NR NR NR NR 
SBP (mmHg) 120.9 
(23.0) 
121.8 
(18.3) 
126.8 
(20.2) 
128.5 
(17.1) 
147.4 
(22.6) 
136.2 
(21.9) 
142.7 
(21.9) 
138.4 
(20.4) 
141.3 
(20.2) 
130.3 
(18.9) 
143.8 
(20.8) 
140.1 
(19.8) 
152.7 
(23.0) 
157.1 
(21.4) 
137.4 
(17.6) 
134.3 
(17.7) 
DBP (mmHg) 79.7 
(13.8) 
78.3 
(10.3) 
80.4 
(11.2) 
81.2 
(9.8) 
86.2 
(12.2) 
83.5 
(12.2) 
80.9 
(12.7) 
82.6 
(11.2) 
85.2 
(10.9) 
81.0 
(10.7) 
85.1 
(11.1) 
84.2 
(11.0) 
81.9 
(12.0) 
84.7 
(11.6) 
84.7 
(10.2) 
83.1 
(10.4) 
LDL (mmol/l) 3.18 
(1.03) 
2.70 
(0.85) 
3.22 
(1.13) 
2.77 
(1.02) 
4.08 
(1.15) 
3.65 
(1.16) 
2.89 
(1.10) 
3.31 
(0.95) 
4.77 
(1.11) 
4.16 
(1.08) 
3.93 
(0.97) 
3.76 
(0.91) 
3.72 
(0.74) 
3.78 
(0.80) 
4.99 
(0.45) 
4.60 
(0.45) 
HDL (mmol/l) 0.85 
(0.21) 
0.87 
(0.22) 
0.91 
(0.27) 
0.93 
(0.29) 
1.48 
(0.49) 
1.61 
(0.50) 
1.36 
(0.45) 
1.65 
(0.51) 
1.27 
(0.38) 
1.49 
(0.41) 
1.18 
(0.34) 
1.30 
(0.35) 
1.20 
(0.32) 
1.32 
(0.37) 
1.09 
(0.24) 
1.15 
(0.24) 
Triglycerides 
(mmol/l) 
2.14 
(1.34) 
2.27 
(1.32) 
2.27 
(1.40) 
2.34 
(1.40) 
2.12 
(1.30) 
1.75 
(1.13) 
1.79 
(1.22) 
1.77 
(1.19) 
1.89 
(1.18) 
1.32 
(0.88) 
1.98 
(1.25) 
1.66 
(1.08) 
1.61 
(0.76) 
1.47 
(0.65) 
1.92 
(0.78) 
1.79 
(0.75) 
Total 
cholesterol 
(mmol/l) 
5.13 
(1.12) 
4.71 
(0.99) 
5.06 
(1.35) 
4.66 
(1.30) 
6.23 
(1.28) 
6.05 
(1.28) 
4.86 
(1.28) 
5.73 
(1.06) 
6.41 
(1.17) 
5.91 
(1.12) 
6.10 
(1.11) 
5.92 
(1.05) 
5.57 
(0.84) 
5.68 
(0.90) 
7.03 
(0.59) 
7.00 
(0.59) 
 
eTable 4: Characteristics of  participants from the Exome+ consortium by carriage of loss of function (LoF) variants 157 
 
European South Asians 
 
At least 1 LoF variant No LoF variants At least 1 LoF variant No LoF variant 
N 84 54,145 80 27,747 
Male (n (%)) 41 (48.8) 43 (51.2) 69 (86.3) 22,616 (81.5) 
Age (years) 55.8 (11.9) 57.6 (11.9) 53.2 (10.1) 54.3 (10.0) 
Height (cm) 168.0 (9.1) 168.8 (9.4) 165.7 (7.6) 165.5 (8.4) 
Weight (kg) 74.8 (13.5) 75.7 (14.5) 66.4 (14.5) 69.4 (13.0) 
BMI (kg/m2) 26.6 (4.6) 26.5 (4.3) 24.1 (4.7) 25.3 (4.5) 
WHR (-) 0.87 (0.10) 0.88 (0.10) 0.96 (0.06) 0.96 (0.06) 
SBP (mmHg) 138.6 (23.0) 138.8 (21.1) 122.2 (18.7) 126.4 (19.3) 
DBP (mmHg) 83.6 (12.5) 83.3 (11.4) 79.0 (10.0) 80.5 (10.9) 
LDL (mmol/l) 3.88 (1.17) 3.81 (1.22) 2.84 (1.00) 2.97 (1.07) 
HDL (mmol/l) 1.34 (0.40) 1.44 (0.46) 0.93 (0.30) 0.91 (0.27) 
Triglycerides 
(mmol/l) 1.79 (1.18) 1.71 (1.13) 2.09 (1.53) 2.29 (1.38) 
Total cholesterol 
(mmol/l) 5.78 (1.15) 5.86 (1.25) 4.79 (1.16) 4.86 (1.29) 
Numbers are mean (SD)158 
 
eTable 5: Study-level characteristics of studies of rs76863441 (Val279Phe) and CHD or cardiovascular risk factors 159 
  Study/Author 
name 
Country Control population Case definition N cases N 
controls 
Overall 
minor 
allele 
frequency 
Mean 
age 
% Male Lp-PLA2 
activity 
assay 
Genotyping 
method 
Phenotypes reported by genotype* 
                       Lp-PLA2 
activity 
Lp-PLA2 
mass 
Blood 
pressure 
Lipids Inflamm
ation 
Glucose 
/Diabetes 
Studies with information on V279F and CVD               
 Yamada 1998 & 
2000$ 
Japan Healthy hospital based* MI or stroke 2517 6076 17% 56 66 Spec. PCR √  √ √  √ 
 Hohda 2003 Japan General population MI 136 218 18% 47 76 NA PCR       
 Liu 2006 Taiwan Healthy hospital based* MI before age 45 200 200 17% 41 84 NA Puregene 
DNA 
Isolation Kit 
      
 Li 2011 China Healthy hospital based* AP (with stenosis > 
50%) /MI 
804 482 6% 61 69 NA TaqMan       
 Hou 2009 
(Beijing 
atherosclerosis 
study) 
China General population Non-fatal MI, CAD 
defined by stenosis 
(>70%) 
810 914 5% 53 76 CAM PCR √      
 Jang 2006 & 
2011  (Study 
subset 1 & 2) 
 
South 
Korea 
Healthy volunteers MI, CAD defined by 
stenosis (>50%) 
5874 5222 12% 55 75 Spec. TaqMan √   √   
 Takeuchi 2012 Japan  MI or angina with 
stenosis >75% 
806 1335 20%** 66 64 NA GWAS-
Illumina 
      
Studies with information on V279F and CHD risk factors               
 Ichihara 1998 Japan Healthy hospital based NA NA 226 13% 54 76 Spec. PCR √      
 Yoshida 1998 Japan Healthy hospital based* NA NA 270 18% 61 56 Spec. PCR √      
 Satoh 1999 Japan General population NA NA 111 18% - - Spec. - √      
                  
 Osoegawa 2004 Japan General population NA NA 82 14% - - Spec. PCR √      
 Unno 2006 Japan Healthy hospital based* NA NA 158 17% 71 86 TCA PCR √      
 Zhang 2007 Japan Healthy hospital based* NA NA 2018 17% 58 55 Azwell PCR √  √ √ √  
 Wang 2009 
(Shimane study) 
Japan Healthy hospital based* NA NA 800 19% 64 40 Cayman PCR/Taqma
n 
√  √ √ √  
 Paik 2010 Korea Healthy hospital based* NA NA 2914 13% 57 40 Radiome
tric 
SNaPShot 
assay kit 
√ √ √ √ √ √ 
  Fan 2010 China Hospital Infertile otherwise 
healthy 
NA NA 148 4% 28 0 TCA PCR √  √ √   
*Attending routine check up or screening test and found to lack any serious disorders; **Figures for Takeuchi relate to rs1805018 which is a proxy of rs16874954 in Japanese (r2=0.94)  + stenosis refers to stenosis >50% in at least one 160 
major coronary artery, except in the Beijing atherosclerosis study where it is at least 70%. $Non-overlapping subjects obtained via a data request. AP=angina pectoris; CAD=coronary artery disease; CAM=calorimetric assay method; 161 
MI=myocardial infarction;  PAD=Peripheral arterial disease; PCR=polymerase chain reaction ; Spec.=Spectophometric; TCA=tricalorimetric assay 162 
 163 
 
eTable 6:  Number of cases and controls carrying loss of function variants  164 
 165 
Study Participants 
with loss of 
function 
variants 
Participants 
without loss of 
function variants 
 Cases Controls Cases Controls 
Gln287Ter     
CCHS 1 4 2,019 6,083 
CIHDS/CGPS 7 8 8,072 10,359 
EPIC-CVD 9 10 9,801 10,960 
MORGAM 0 1 2,153 2,117 
PROSPER 0 0 641 638 
WOSCOPS 0 1 659 686 
MICAD 
consortium 
32 51 36,155 64,581 
TOTAL 49 75 59,500 95,424 
     
rs142974898     
CCHS 0 0 2,020 6,087 
CIHDS/CGPS 0 0 8,079 10,367 
EPIC-CVD 3 4 9,807 10,966 
MORGAM 1 0 2,152 2,118 
PROSPER 0 0 641 638 
WOSCOPS 0 0 659 687 
MICAD 
consortium 
Not assayed 
European total 4 4 23,358 30,863 
BRAVE 0 0 2,971 2,782 
PROMIS 0 0 10,135 11,928 
South Asian 
total 
0 0 13,106 14,710 
TOTAL 4 4 36,464 45,573 
     
     
Arg82His     
CCHS 0 2 2,020 6,085 
CIHDS/CGPS 1 0 8,078 10,367 
EPIC-CVD 2 8 9,808 10,962 
MORGAM 2 2 2,151 2,116 
PROSPER 1 0 640 638 
WOSCOPS 2 0 657 687 
MICAD 
consortium 
14 23 36,173 64,609 
European total 22 35 59,527 95,464 
BRAVE 13 6 2,958 2,776 
PROMIS 10 14 10,125 11,914 
South Asian 
total 
23 20 13,083 14,690 
TOTAL 45 55 72,610 110,154 
     
     
Val279Phe     
CCHS 0 1 2,020 6,086 
CIHDS/CGPS 0 2 8,079 10,365 
EPIC-CVD 5 6 9,805 10,964 
MORGAM 0 1 2,153 2,117 
PROSPER 0 0 641 638 
WOSCOPS 0 0 659 687 
MICAD 
consortium 
11 20 36,176 64,612 
European total 16 30 59,533 95,469 
 
BRAVE 10 10 2,961 2,772 
PROMIS 7 10 10,128 11,918 
South Asian 
total 
17 20 13,089 14,690 
TOTAL 33 50 72,622 110,159 
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